Replimune Group (NASDAQ:REPL) Trading Down 6.6% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s share price traded down 6.6% during mid-day trading on Monday . The stock traded as low as $10.44 and last traded at $10.2610. Approximately 245,496 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 4,548,816 shares. The stock had previously closed at $10.99.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the company. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. BMO Capital Markets raised shares of Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a research note on Tuesday, June 30th. Leerink Partners reiterated a “market perform” rating and set a $2.00 price target (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. JPMorgan Chase & Co. upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 price target for the company in a research report on Friday, June 26th. Finally, Cantor Fitzgerald lowered shares of Replimune Group from an “overweight” rating to a “hold” rating in a report on Monday, April 13th. Two equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Replimune Group has an average rating of “Hold” and a consensus target price of $8.12.

Replimune Group Stock Performance

The company has a market cap of $828.49 million, a price-to-earnings ratio of -2.92 and a beta of 0.86. The company has a debt-to-equity ratio of 0.63, a current ratio of 4.79 and a quick ratio of 4.79. The stock has a 50-day moving average price of $8.31 and a 200 day moving average price of $7.38.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Monday, June 29th. The company reported ($0.76) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by ($0.10). As a group, analysts anticipate that Replimune Group, Inc. will post -2.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider owned 180,962 shares of the company’s stock, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Large investors have recently made changes to their positions in the stock. RTW Investments LP raised its holdings in shares of Replimune Group by 11.6% during the fourth quarter. RTW Investments LP now owns 7,140,352 shares of the company’s stock worth $69,404,000 after acquiring an additional 744,620 shares during the period. State Street Corp boosted its stake in Replimune Group by 26.3% in the 4th quarter. State Street Corp now owns 3,693,107 shares of the company’s stock worth $35,897,000 after purchasing an additional 768,982 shares during the period. Vanguard Group Inc. boosted its stake in Replimune Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after purchasing an additional 9,707 shares during the period. Balyasny Asset Management L.P. boosted its stake in Replimune Group by 507.4% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares during the period. Finally, Toronto Dominion Bank increased its holdings in Replimune Group by 62.5% during the 4th quarter. Toronto Dominion Bank now owns 2,229,527 shares of the company’s stock worth $21,671,000 after purchasing an additional 857,475 shares in the last quarter. Institutional investors own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.